Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

Lilly Inks $2.25B Deal with Profluent for DNA Editing Tools

Eli Lilly has partnered with AI biotech Profluent Bio in a research pact potentially worth up to $2.25 billion to develop advanced DNA editing tools. The collaboration aims to create more precise treatments for genetic conditions with severe unmet needs by leveraging Profluent's AI models to design site-specific recombinases. This initiative focuses on achieving kilobase-scale DNA editing, a challenging goal in genetic medicine, to enable the insertion of larger DNA pieces than currently possible. Lilly will gain exclusive licensing rights for selected assets for preclinical, clinical development, and commercialization.

• The collaboration centers on Profluent's AI models to design site-specific recombinases, enzymes crucial for cutting and rejoining DNA. This technology is aimed at enabling "kilobase-scale DNA editing," a significant advancement that could allow for the insertion of larger DNA segments to address complex genetic diseases caused by multiple mutations, which are currently difficult to target with existing methods.
• Profluent will receive an undisclosed upfront payment and is eligible for up to $2.25 billion in development and commercial milestone payments, along with royalties on net sales. This substantial financial commitment from Lilly underscores the potential value and strategic importance placed on Profluent's AI-driven platform for developing next-generation genetic medicines.
• This deal marks another step in Eli Lilly's aggressive dealmaking and commitment to artificial intelligence in drug discovery. It complements previous AI partnerships and acquisitions, reinforcing Lilly's strategy to leverage cutting-edge technology to accelerate the development of treatments for genetic conditions, moving beyond its recent focus on oncology and into advanced gene editing solutions.

Why Kilobase-Scale DNA Editing is the 'Holy Grail'

Kilobase-scale DNA editing has emerged as a transformative approach to address longstanding therapeutic gaps in genetic medicine. Recent literature highlights several critical unmet needs and target populations that could benefit from advanced genetic interventions. The focus has shifted toward addressing complex genetic disorders that require large-scale genomic modifications beyond the scope of traditional gene editing techniques.

• Rare disease populations globally comprise 3.5%-5.9% of the population (approximately 400 million people worldwide), with particular emphasis on underserved populations in the Global South, especially India, where scientific, clinical, and economic gaps require establishment of rare disease platforms to transform untapped genetic diversity into therapeutic opportunities

• Monogenic disorders affecting multiple life stages represent a key target, with clinical genome sequencing analysis of 15,644 individuals (48% pediatric, 48% adult, 4% fetal) achieving only 22.6% diagnostic yield, highlighting the need for more comprehensive genetic interventions for conditions like familial hypercholesterolemia and inborn errors of metabolism

• Complex cardiovascular genetic conditions including cardiomyopathies that substantially contribute to heart failure, requiring advanced gene therapy approaches such as gene silencing, CRISPR genome editing, and sarcomere function enhancement beyond current treatment limitations

• Hemophilia and sickle cell disease patients who achieved major regulatory milestones for gene therapies in 2024, yet face challenges with affordability and equitable access despite breakthrough approvals, particularly affecting underserved populations globally

• Inherited retinal diseases including RPE65-mediated retinal dystrophy, with multiple early-phase clinical trials underway for both inherited and acquired retinal diseases, representing a growing target population for ocular gene therapies

• Cancer populations with resistant tumors requiring sophisticated approaches to address tumor heterogeneity, immune evasion, and immunosuppressive tumor microenvironments, with both hematologic malignancies and solid tumors being targeted through gene replacement, CAR-T cell therapy, and CRISPR-Cas9 editing

• African populations with epilepsy affecting an estimated 25 million people face significant unmet needs due to limited access to appropriate medications, social stigma, and inadequate research infrastructure, with phenobarbital remaining the primary available treatment despite efficacy and safety limitations

Lilly's Strategic Vision in Genetic Medicine

The therapeutic landscape for genetic conditions has undergone dramatic expansion over the past five years, with multiple novel treatment modalities emerging from clinical trials. Published data reveals a comprehensive arsenal of approaches now available for rare genetic disorders, including protein replacement therapies, small molecule interventions (substrate reduction therapy, chemical chaperone therapy, cofactor therapy), monoclonal antibodies, antisense oligonucleotides, small interfering RNA therapies, gene replacement strategies, direct genome editing, mRNA therapy, and cell therapy approaches. Gene-editing technologies utilizing platforms like CRISPR-Cas9 have advanced significantly, enabling personalized treatments that target the root molecular causes of genetic diseases. Despite this therapeutic diversification, only four gene therapies achieved FDA and/or EMA approval for clinical use as of recent data, including breakthrough approvals for hemophilia treatments such as valoctocogene roxaparvovec (ROCTAVIAN) for severe hemophilia A and etranacogene dezaparvovec (HEMGENIX) for severe hemophilia B.

Clinical trial methodologies have evolved substantially to address the unique challenges posed by rare genetic diseases, particularly those with predominant central nervous system involvement and heterogeneous clinical manifestations. Critical trial design innovations include strategic patient selection and recruitment protocols, refined endpoint identification, optimized study duration determination, implementation of natural history controls, and sophisticated statistical analysis frameworks. The integration of in vitro cell-based data has enabled regulatory approval extensions to patient subsets with unique genetic variants, provided that disease mechanisms are well-characterized and drug mechanisms of action align with disease pathophysiology. In utero enzyme replacement therapy has emerged as a promising approach for lysosomal storage diseases, offering advantages including pre-symptomatic intervention, tolerance development, and enhanced central nervous system penetration through the more permeable fetal blood-brain barrier.

The precision medicine paradigm has been revolutionized through multi-omics integrative approaches combining genomics, transcriptomics, and epigenomics data with artificial intelligence and machine learning algorithms for pattern recognition and biomarker discovery. Modern genetic technologies now enable precise identification of disease-relevant genes and molecular pathways, while advanced computational methods facilitate accurate diagnosis even with limited sample sizes typical of rare diseases. However, significant systemic barriers persist, with most rare diseases still lacking approved treatments despite substantial research advances and regulatory incentives. Clinical trials continue to face challenges including patient recruitment difficulties, incomplete understanding of disease natural history, pediatric ethical considerations, and complex regulatory requirements, necessitating collaborative engagement among academic institutions, industry, patient advocacy organizations, and regulatory bodies to bridge the translational gap between scientific knowledge and therapeutic implementation.

Lilly's Bold Bet on AI-Driven Genomic Tooling

Eli Lilly's recent research pact with AI biotech Profluent Bio, a collaboration potentially valued at up to $2.25 billion, signals a significant strategic move into the frontier of genomic medicine. This partnership is not merely about developing another drug; it's about engineering the very tools that will enable the next generation of genetic therapies. By leveraging Profluent's advanced AI models to design site-specific recombinases, Lilly is making a bold bet on the power of artificial intelligence to unlock capabilities previously out of reach.

The core ambition here is to achieve kilobase-scale DNA editing, a challenging yet transformative goal. Current gene editing technologies often struggle with inserting larger pieces of DNA, limiting their utility for many complex genetic conditions. Success in kilobase-scale editing could mean more precise and comprehensive treatments for severe unmet needs, potentially correcting larger genetic defects that cause debilitating diseases. This initiative underscores a broader trend in the pharmaceutical industry where AI is increasingly seen as a complementary, rather than a replacement, tool, now extending its influence from small molecule discovery to the intricate design of biological systems.

However, this ambitious endeavor is not without its considerations. While AI can dramatically accelerate discovery timelines, research shows that this acceleration does not guarantee clinical success; some AI-assisted compounds have faced discontinuation in early clinical phases despite promising safety profiles. The technical hurdles associated with achieving reliable and safe kilobase-scale DNA editing are substantial, representing a significant development risk. Furthermore, as with any groundbreaking genetic technology, the path forward will undoubtedly involve navigating complex regulatory landscapes and addressing evolving ethical considerations, which could impact the pace and scope of development. Despite these challenges, Lilly's investment positions the company as a potential leader in the foundational technologies that will shape the future of genetic medicine.